Effect of Aducanumab Approval on Willingness to Participate in Preclinical Alzheimer's Disease Trials.

MLA

Ritchie, Marina, et al. “Effect of Aducanumab Approval on Willingness to Participate in Preclinical Alzheimer’s Disease Trials.” Journal of Alzheimer’s Disease : JAD, vol. 90, no. 3, 2022, pp. 1291–300. EBSCOhost, https://doi.org/10.3233/JAD-220801.

APA

Ritchie, M., Witbracht, M., Nuño, M. M., Hoang, D., Gillen, D. L., & Grill, J. D. (2022). Effect of Aducanumab Approval on Willingness to Participate in Preclinical Alzheimer’s Disease Trials. Journal of Alzheimer’s Disease : JAD, 90(3), 1291–1300. https://doi.org/10.3233/JAD-220801

Chicago

Ritchie, Marina, Megan Witbracht, Michelle M Nuño, Dan Hoang, Daniel L Gillen, and Joshua D Grill. 2022. “Effect of Aducanumab Approval on Willingness to Participate in Preclinical Alzheimer’s Disease Trials.” Journal of Alzheimer’s Disease : JAD 90 (3): 1291–1300. doi:10.3233/JAD-220801.